Literature DB >> 20206671

Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model.

Melissa J Whaley1, Jacquelyn S Sampson, Scott E Johnson, Gowrisankar Rajam, Annie Stinson-Parks, Patricia Holder, Erica Mauro, Sandra Romero-Steiner, George M Carlone, Edwin W Ades.   

Abstract

A murine colonization model was used to determine the effect of co-administering 7-valent polysaccharide-protein conjugate vaccine and pneumococcal surface adhesin A. Mice were challenged intranasally with either PCV7 serotypes, 4 or 14, or a non-PCV7 serotype, 19A. Post-challenge samples were evaluated for IgG antibody levels, opsonophagocytic activity, and nasopharyngeal colonization. No interference was observed between immune responses from the concomitant and individual immunizations. Concomitant immunizations reduced carriage for tested serotypes; largest reduction was observed for 19A. From these mouse studies, co-administering pneumococcal antigens appear to expand coverage and reduce colonization against a non-PCV7 serotype without inhibiting immunogenicity to other serotypes. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206671     DOI: 10.1016/j.vaccine.2010.02.086

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Next generation pneumococcal vaccines.

Authors:  Kristin L Moffitt; Richard Malley
Journal:  Curr Opin Immunol       Date:  2011-04-21       Impact factor: 7.486

2.  Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity.

Authors:  Fan Zhang; Ying-Jie Lu; Richard Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

3.  Two DHH subfamily 1 proteins contribute to pneumococcal virulence and confer protection against pneumococcal disease.

Authors:  L E Cron; K Stol; P Burghout; S van Selm; E R Simonetti; H J Bootsma; P W M Hermans
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

Review 4.  Pneumococcal Surface Proteins as Virulence Factors, Immunogens, and Conserved Vaccine Targets.

Authors:  Javid Aceil; Fikri Y Avci
Journal:  Front Cell Infect Microbiol       Date:  2022-05-12       Impact factor: 6.073

5.  Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.

Authors:  Xiaorui Chen; Bo Li; Jinfei Yu; Yue Zhang; Zujian Mo; Tiejun Gu; Wei Kong; Yong Zhang; Yongge Wu
Journal:  Med Microbiol Immunol       Date:  2019-02-01       Impact factor: 3.402

Review 6.  Rationale and prospects for novel pneumococcal vaccines.

Authors:  Kristin Moffitt; Richard Malley
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

7.  A chitosan-based nanosystem as pneumococcal vaccine delivery platform.

Authors:  Sandra Robla; Maruthi Prasanna; Rubén Varela-Calviño; Cyrille Grandjean; Noemi Csaba
Journal:  Drug Deliv Transl Res       Date:  2021-03-02       Impact factor: 4.617

Review 8.  Manganese acquisition and homeostasis at the host-pathogen interface.

Authors:  John P Lisher; David P Giedroc
Journal:  Front Cell Infect Microbiol       Date:  2013-12-05       Impact factor: 5.293

9.  Site-Specific Conjugation for Fully Controlled Glycoconjugate Vaccine Preparation.

Authors:  Aline Pillot; Alain Defontaine; Amina Fateh; Annie Lambert; Maruthi Prasanna; Mathieu Fanuel; Muriel Pipelier; Noemi Csaba; Typhaine Violo; Emilie Camberlein; Cyrille Grandjean
Journal:  Front Chem       Date:  2019-11-01       Impact factor: 5.221

10.  Characterization of Two Metal Binding Lipoproteins as Vaccine Candidates for Enterococcal Infections.

Authors:  Felipe Romero-Saavedra; Diana Laverde; Aurélie Budin-Verneuil; Cécile Muller; Benoit Bernay; Abdellah Benachour; Axel Hartke; Johannes Huebner
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.